TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06631872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-prehabilitation education session: Surgery School
Description: Online telehealth education program using videos and a live clinician facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation education session: Surgery School
Description: Online telehealth education program using videos and a live clinician facilitator
Study: NCT05552404

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative therapy
Description: bed rest, fluids, abdominal binder, oral paracetamol, and caffeine

Intervention type: OTHER
Group type: OTHER
Intervention: conservative therapy
Description: bed rest, fluids, abdominal binder, oral paracetamol, and caffeine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative therapy
Description: bed rest, fluids, abdominal binder, oral paracetamol, and caffeine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trans nasal sphenopalatine ganglion block
Description: conservative therapy plus sphenopalatine ganglion block SPGB using hollow cotton swab and lidocaine 2%
Study: NCT05757687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega device
Description: The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.
Study: NCT05954975

Intervention type: COMBINATION_PRODUCT
Intervention: BabyCheck and pulse oximetry
Description: The BabyCheck is a validated scoring system to grade the severity of acute systemic illness in infants up to six months of age. Severity of illness is graded by using a weighted score of a combination of nineteen signs and symptoms. The higher the score, the higher the chance of severe illness.~Nellcor PM10N is a pulse oximeter which is cleared for use in young infants. A sensor for infants will be used, so reliable oxygen saturation and heart rate can be obtained.
Study: NCT06631872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualised Inspiratory Muscle Training and Walking Program
Description: An individualised inspiratory muscle training and walking program delivered by a Physiotherapist using telehealth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care alone. Usual care will be reviewed every four months during the trial and site leads will be asked to provide information about any changes to usual hospital and medical care at their site.
Study: NCT05821322

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity trial intervention
Description: 60 minutes aerobic ergocyle exercice at 60% VO2 Peak

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity trial intervention
Description: 60 minutes aerobic ergocyle exercice at 60% VO2 Peak

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity trial intervention
Description: 60 minutes aerobic ergocyle exercice at 60% VO2 Peak
Study: NCT05954832

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography and Clearsight BP measurements before, immediately after anesthesia induction and after intubation (for 20 min)
Study: NCT05700747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Through Activity
Description: Six, weekly, customized sessions with licensed physical and occupational therapists.
Study: NCT05592353

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brace
Description: Brace following hip arthroscopy
Study: NCT06094998

Intervention type: DIAGNOSTIC_TEST
Intervention: hemogram examination
Description: It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.

Intervention type: DIAGNOSTIC_TEST
Intervention: hemogram examination
Description: It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
Study: NCT03070691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225B
Description: Cream, 2x daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: cream, 2x daily
Study: NCT04984421

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy School Start
Description: The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy School Start
Description: The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.
Study: NCT05666518

Intervention type: DRUG
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: Dosage at the discretion of the treating physician, based on the recommendations written in the product information.

Intervention type: DRUG
Intervention: Standard of care
Description: Dosage at the discretion of the treating physician
Study: NCT05814497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Task
Description: Reversing checkerboard, tones, and finger opposition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Task
Description: Reversing checkerboard, tones, and finger opposition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Task
Description: Reversing checkerboard, tones, and finger opposition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Task
Description: Reversing checkerboard, tones, and finger opposition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Task
Description: Reversing checkerboard, tones, and finger opposition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphesthesia
Description: Trace numbers on skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphesthesia
Description: Trace numbers on skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphesthesia
Description: Trace numbers on skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphesthesia
Description: Trace numbers on skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphesthesia
Description: Trace numbers on skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Divided attention
Description: Divide attention between two noxious stimuli.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Divided attention
Description: Divide attention between two noxious stimuli.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Divided attention
Description: Divide attention between two noxious stimuli.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Divided attention
Description: Divide attention between two noxious stimuli.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Divided attention
Description: Divide attention between two noxious stimuli.
Study: NCT04646187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Dosing interval lengthening from 8 to 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Dosing interval lengthening from 2 to 3 weeks
Study: NCT06395012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3985297
Description: Administered either IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3985297
Description: Administered either IV or SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered either IV or SC.
Study: NCT05458908

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-contrast cranial MDCT head scan
Description: Non-contrast cranial MDCT imaging for visualization of the brain parenchyma (the choice of the device is up to the investigator)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-contrast syngo DynaCT Sine Spin head scan and application software
Description: Non-contrast syngo DynaCT Sine Spin imaging for visualization of the brain parenchyma with ARTIS icono biplane angiography system and syngo application software with syngo DynaCT Sine Spin 3-D head imaging protocol.
Study: NCT06546007

Intervention type: DIAGNOSTIC_TEST
Intervention: CTC-DNA
Description: ctDNA for the analysis of lung cancer mutations in patients with operable tumors.
Study: NCT05923684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NLP-based Feedback
Description: Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
Study: NCT06104345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral typhoid fever vaccine
Description: Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral typhoid fever vaccine
Description: Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral cholera vaccine
Description: Oral cholera vaccine (Dukoral®) on Days 0 and 7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine
Description: Oral cholera vaccine (Dukoral®) on Days 0 and 7.
Study: NCT04840511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine group
Description: lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
Study: NCT05849558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursoplus
Description: Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA 250mg
Description: UDCA 250mg alone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo alone
Study: NCT06140693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise at an intensity below the ventilatory threshold
Description: 30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 80% of the intensity at the ventilatory threshold
Study: NCT05990504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound real-time guidance combined with Dural Puncture Epidural Labor Anagesia
Description: Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound real-time guidance combined with Epidural Labor Anagesia
Description: Epidural is a traditional labor analgesia technique.
Study: NCT05364671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raphamin
Description: Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
Study: NCT05420324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be administered intravenously over 30 minutes every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel
Description: Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
Study: NCT05650086

Intervention type: DEVICE
Intervention: Thermalytix
Description: One-time Thermal imaging is performed for this cohort.
Study: NCT06140693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise at an intensity at the ventilatory threshold
Description: 30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 100% of the intensity at the ventilatory threshold

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise at an intensity above the ventilatory threshold
Description: 30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 110% of the intensity at the ventilatory threshold
Study: NCT05650086

Intervention type: DEVICE
Intervention: Thermalytix
Description: One-time Thermal imaging is performed for this cohort.

Intervention type: DEVICE
Intervention: Thermalytix
Description: One-time Thermal imaging is performed for this cohort.

Intervention type: DEVICE
Intervention: Thermalytix
Description: One-time Thermal imaging is performed for this cohort.
Study: NCT05169697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A:YH002+YH001
Description: YH002 on CnD1,YH001 on CnD8,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B:YH002+YH001
Description: YH002 and YH001 on same day,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH002+YH001
Description: A traditional 3+3 dose escalation algorithm
Study: NCT05794022

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: 1 MRI at 1 month with gadolinium injection
Study: NCT06140693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint interval training
Description: 22 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by four 30-s 'all-out' sprints, each with a 4-min recovery intervals at 25 W

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced-exertion high-intensity interval training
Description: 10 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by two 20-s 'all-out' sprints, with a 3-min and a 4-min recovery interval at 25 W after the first and second sprint respectively
Study: NCT05661162

Intervention type: DEVICE
Group type: OTHER
Intervention: CR 500™ SINGLE-DOSE GEL
Description: CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
Study: NCT04672590

Intervention type: OTHER
Intervention: Primary exposure is hypoxia (no intervention)
Description: The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.

Intervention type: OTHER
Intervention: Primary exposure is hypoxia (no intervention)
Description: The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.
Study: NCT06037187

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling
Study: NCT04538820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg IV-control
Description: dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg IV
Description: dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg IV
Description: dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
Study: NCT05794022

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biocollection
Description: Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life questionaries
Description: EQ-5D-5L and HAD questionaries at 1 month and 1 year.
Study: NCT04841434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voraxaze Injectable Product
Description: High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to \<40 mL/min, or in the case of decreased GFR, the decrease is \>50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing \>100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
Study: NCT05360459

Intervention type: RADIATION
Intervention: Exposure to radiotherapy
Description: Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
Study: NCT06412029

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-interventional study

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-interventional study

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-interventional study
Study: NCT00881413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months